Status:

COMPLETED

Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults

Lead Sponsor:

CSL Behring

Conditions:

Healthy Volunteers

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

Brief Summary

This is a phase I, single-center, randomized, open-label, single-dose, 2-way, 2-period, crossover study to evaluate the effect of food on the pharmacokinetics (PK) of vamifeport prolonged-release (PR)...

Eligibility Criteria

Inclusion

  • •Aged greater than or equal to (\>=) 18 to less than or equal to (\<=) 60 years at the time of providing written informed consent.
  • •Healthy, as determined by the investigator based on review of defined assessments during Screening.
  • •Body weight between 50 and 100 kilogram (kg) (inclusive) and body mass index within the range 18.0 to 30.0 kg per square metre (kg/m2) (inclusive) at Screening and Day - 1.

Exclusion

  • •Any clinically relevant abnormal means of triplicate 12-lead ECG finding at Screening or Day - 1 (as deemed by the investigator).
  • •Serum ferritin of less than (\<) 30 nanograms per milliliter (ng/mL) or greater than (\>) 300 ng/mL for assigned male at birth (AMAB) participants or \< 16 ng/mL or \> 300 ng/mL for assigned female at birth (AFAB) participants at Screening or Day - 1.
  • •Hemoglobin \< 13 gram per deciliter (g/dL) (8.1 millimole per liter \[mmol/L\]) for AMAB participants or \< 12 g/dL (7.5 mmol/L) for AFAB participants at Screening or Day - 1.
  • •Blood draw or donation of blood (\>= 450 mL) within 3 months before Screening, plasma donation from 2 weeks before Screening, or platelet donation from 6 weeks before Screening.

Key Trial Info

Start Date :

May 27 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 4 2025

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT06996184

Start Date

May 27 2025

End Date

July 4 2025

Last Update

November 21 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Investigator Site 82600083

Leeds, West Yorkshire, United Kingdom, LS11 9E

Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults | DecenTrialz